A complete analysis of the efficacy and mechanism of bevacizumab

Bevacizumab (Bevacizumab) is a humanized monoclonal antibody made by recombinant DNA technology. It is one of the most important drugs widely used in the field of anti-tumor targeted therapy. It does not belong to traditional chemotherapy drugs, nor does it directly kill tumor cells. Instead, it inhibits the angiogenesis process that tumors rely on to survive, and cuts off the tumor's "oxygen supply channel" from the source, thereby inhibiting tumor growth and delaying the progression of the disease. This unique treatment modality, known as "anti-angiogenic therapy," plays a key role in comprehensive treatment regimens for malignant tumors, especially in a variety of solid tumors such as metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and brain glioblastoma.

The core mechanism of action of bevacizumab is to target and neutralize a cytokine called vascular endothelial growth factorA (VEGF-A). VEGF-A is a pro-angiogenic signaling molecule that is secreted in large quantities in the tumor microenvironment. It can stimulate endothelial cell proliferation, migration and the formation of new blood vessels. Tumor tissue is often in a hypoxic state due to rapid proliferation, and new blood vessels are its main way of obtaining oxygen and nutrients. Therefore, the activity of VEGF is crucial for tumor growth, invasion and distant metastasis. Bevacizumab binds to VEGF-A with high affinity and prevents it from binding to receptors on the surface of vascular endothelial cells (such as VEGFR-1 and VEGFR-2), thereby inhibiting downstream angiogenesis signaling pathways. As a result, the formation of new blood vessels is inhibited, the original abnormal blood vessel structure degenerates, the blood supply to the tumor is reduced, tissue hypoxia is aggravated, and the growth rate of tumor cells is significantly slowed down, and even necrosis occurs.

In addition to the effect of "starving" tumors, bevacizumab has another important synergistic mechanism, which is "blood vessel normalization." New blood vessels in tumors often have a disordered structure, high permeability, and poor blood flow, which results in the inability of chemotherapy drugs to effectively reach the core of the tumor. By inhibiting the excessive proliferation of abnormal blood vessels, bevacizumab makes the remaining blood vessels more structurally reasonable and functional, thereby improving local blood flow and creating better conditions for the penetration of subsequent chemotherapy drugs or immune cells. This mechanism also explains why bevacizumab is often used in combination with chemotherapy drugs or immune checkpoint inhibitors, with the goal of enhancing anti-tumor activity while optimizing the overall effect of treatment.

As a targeted therapy, one of the advantages of bevacizumab is that it has low toxicity to normal cells, so its overall tolerability is better than traditional cytotoxic drugs. Bevacizumab has been recognized as an important component of standard first- or second-line therapy in multiple oncology treatment guidelines. For example, in metastatic colorectal cancer, bevacizumab was used in combination with fluorouracil-containing chemotherapy regimens, which significantly prolonged the progression-free survival and overall survival of patients; in non-small cell lung cancer, bevacizumab was used in combination with paclitaxel/carboplatin combination regimen has become a conventional strategy for the treatment of non-squamous types; in diseases with extremely poor prognosis such as recurrent glioblastoma, bevacizumab provides patients with a new option for symptom control and delaying progression.

It is worth mentioning that although bevacizumab works through an anti-angiogenic mechanism, its clinical manifestations vary significantly depending on tumor type, genetic characteristics, timing of administration, and combination with other drugs. Some tumor types are more sensitive to it, while others may only respond to patients with certain molecular characteristics. Therefore, in actual treatment, doctors will evaluate whether bevacizumab is suitable for use based on the patient's specific pathological characteristics, gene expression, and disease progression, and formulate an individualized treatment plan.

Reference materials:https://www.drugs.com/bevacizumab.html